

Comprehensive  *NeuroScience*

***Alaska Medicaid BPM
Stakeholders' Meeting***

September, 2006

Changes in BPMS Project

2005 VS 2006

- **Adults (18 and older) and Children/Adolescents (under 18)**
- **Quality Indicator™ Letters mailed for Adults and Children both each month**
- **Adult BPM Program**
 - 26 adult Quality Indicators™ for monthly reporting
- **Child/Adolescent BPM Program**
 - 1 Child/Adolescent Quality Indicators™ for monthly reporting
- **Same as 2005**
- **Quality Indicator™ Letters mailed for Adults and Children on alternate months to allow more time for changes in prescribing practices between mailings**
- **Adult BPM Program**
 - 36 adult Quality Indicators™ for monthly reporting
 - More focus on adults from TANF eligible Medicaid recipients
 - Increased focus on opiates, insomnia agents, and polypharmacy
- **Child/Adolescent BPM Program**
 - 23 Child/Adolescent Quality Indicators™ for monthly reporting
 - More focus on Children from TANF eligible Medicaid recipients
 - Increased focus on ADHD drugs

Two Alaska BPMS Projects

- Medicaid BPMS Project – health benefit program (including pharmacy) for Medicaid only eligible persons
- ASEA Health Benefits Trust (ASEA) – health insurance program for full-time and seasonal employees Alaska State employees



Effect of January 1, 2006 Implementation of Medicare Part D

- **January 1, 2006 - All Medicaid eligible enrollees eligible for both Medicare and Medicaid due to disability re-enrolled in commercial plans**

11,500 patients were dually eligible

An approximate 12% reduction in covered lives

- **State no longer responsible for behavioral pharmacy needs except where meds are medically necessary but not covered by new plans i.e. benzodiazapines.**

Adult Patients Setting Indicators at December 2005 – 2,750

Adult Patients Setting Indicators at June 2006 – 1,684

Child/Adolescent Patients Hitting Indicators at December 2005 – 512

Child/Adolescent Patients Hitting Indicators at June 2006 -- 379

Recent Changes in Child/Adolescent High Dose Level (mg) by Age Band

- **The Amphetamines (Methamphetamine and Dextroamphetamine) dose was increased from >40 to >60 for the 13-17 age band**
- **Methylphenidate (both long- and short-acting) dose was increased from >65 to >72 for the 13-17 age band to align with the Strattera label**
- **Quetiapine was increased from >600 to >800 for the 13-17 age band**

Mailings in 2006

- **Eight Mailings Completed Year to Date**
- **Orientation Mailing**
1,999 packets
- **Four Mailings on Children and Adolescents**
407 packets
- **Three Mailings on Adults**
636 packets
- **Total Packets Mailed – 3,042**
- **Fourth Mailing on Adults Goes Out in September**




The background is a solid blue color with several large, overlapping, wavy shapes in a slightly lighter shade of blue, creating a sense of movement and depth. The text is centered and rendered in a bold, italicized, yellow font with a black outline.

***Executive Management
Report***

August, 2004 to March, 2006



Monthly Behavioral Rx Cost

Executive Management Report Alaska August 2004 to March 2006




Note: Descriptive data not intended as a measure of CNS's intervention. — Intervention Date

Decrease in Monthly Behavioral Rx Claims




Variance between Expected and Actual Monthly Behavioral Rx Claims Spend



***Select Patient and
Prescriber Data
Comparing
April, 2006 to June, 2006***


Quality Indicator: Use of Antipsychotic at Higher Than Recommended Dose (Under 18 Years)

- The number of **patients** associated with this indicator decreased from 80 to 64 (20%) in two months.




Quality Indicator: Multiple Prescribers of Any Psychotropic Drug for 45 or More Days (Under 18 Years)

- The number of **patients** associated with this indicator decreased from 53 to 41 (23%) in two months.




Quality Indicator: Adults Use of Three or More Psychotropic Drugs

- The number of **patients** associated with this indicator decreased from 541 to 516 (5%) in two months.




Quality Indicator: Adults Use of Atypical Antipsychotic at Higher Than Recommended Dose for 45 or More Days

- The number of **patients** associated with this indicator decreased from 126 to 114 (9%) in two months.



Quality Indicator: Adults Use of 2 or More Antipsychotics for 60 or More Days

- The number of **prescribers** associated with this indicator increased from 110 to 135 (23%) in 3 months.



Medicaid Preferred Drug List

- Contains medications that are 1st choice of the Medicaid Program
 - Clinically effective medications
 - Determined to be appropriate by Committee of professionals, Doctors, Pharmacists, Nurse Practitioner
 - Next review includes Hypnotic, Anti-Depressants (SSRI, SNRI), ADHD, Anti-convulsants
 - If the prescriber orders a non-preferred drug, write; "Medically Necessary"



General Discussion

- **Please be sure to complete the questionnaire and submit it to Ann Swink, either in person, at this meeting, or via the fax number listed at the bottom of the questionnaire.**

THANK YOU!